Telomir Pharmaceuticals (TELO) Expected to Announce Quarterly Earnings on Tuesday

Telomir Pharmaceuticals (NASDAQ:TELO) will likely be issuing its results before the market opens on Tuesday, November 11th. Analysts expect the company to announce earnings of ($0.07) per share for the quarter.

Telomir Pharmaceuticals (NASDAQ:TELO) last released its quarterly earnings results on Thursday, August 14th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.09). On average, analysts expect Telomir Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Telomir Pharmaceuticals Trading Down 2.0%

NASDAQ:TELO opened at $1.47 on Tuesday. The company’s 50-day moving average price is $1.46 and its 200-day moving average price is $1.76. Telomir Pharmaceuticals has a twelve month low of $1.12 and a twelve month high of $7.08. The company has a market cap of $47.45 million, a P/E ratio of -2.72 and a beta of -0.54.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Telomir Pharmaceuticals in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Telomir Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $15.00.

Institutional Investors Weigh In On Telomir Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of TELO. Qube Research & Technologies Ltd bought a new stake in Telomir Pharmaceuticals in the second quarter worth about $33,000. Bank of America Corp DE raised its stake in shares of Telomir Pharmaceuticals by 283.9% in the fourth quarter. Bank of America Corp DE now owns 14,713 shares of the company’s stock valued at $61,000 after purchasing an additional 10,880 shares in the last quarter. Jane Street Group LLC acquired a new position in Telomir Pharmaceuticals during the second quarter worth $62,000. Finally, Marshall Wace LLP acquired a new stake in shares of Telomir Pharmaceuticals in the second quarter valued at $95,000.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.